Rapid in vivo assessment of drug efficacy against Mycobacterium tuberculosis using an improved firefly luciferase
Open Access
- 30 April 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 68 (9) , 2118-2127
Abstract
In vivo experimentation is costly and time-consuming, and presents a major bottleneck in anti-tuberculosis drug development. Conventional methods rely on the enumeration of bacterial colonies, and it can take up to 4 weeks for Mycobacterium tuberculosis to grow on agar plates. Light produced by recombinant bacteria expressing luciferase enzymes can be used as a marker of bacterial load, and disease progression can be easily followed non-invasively in live animals by using the appropriate imaging equipment. The objective of this work was to develop a bioluminescence-based mouse model of tuberculosis to assess antibiotic efficacy against M. tuberculosis in vivo. We used an M. tuberculosis strain carrying a red-shifted derivative of the firefly luciferase gene (FFlucRT) to infect mice, and monitored disease progression in living animals by bioluminescence imaging before and after treatment with the frontline anti-tuberculosis drug isoniazid. The resulting images were analysed and the bioluminescence was correlated with bacterial counts. Using bioluminescence imaging we detected as few as 1.7 × 103 and 7.5 × 104 reporter bacteria ex vivo and in vivo, respectively, in the lungs of mice. A good correlation was found between bioluminescence and bacterial load in both cases. Furthermore, a marked reduction in luminescence was observed in living mice given isoniazid treatment. We have shown that an improved bioluminescent strain of M. tuberculosis can be visualized by non-invasive imaging in live mice during an acute, progressive infection and that this technique can be used to rapidly visualize and quantify the effect of antibiotic treatment. We believe that the model presented here will be of great benefit in early drug discovery as an easy and rapid way to identify active compounds in vivo.Keywords
This publication has 26 references indexed in Scilit:
- A new in vivo model to test anti-tuberculosis drugs using fluorescence imagingJournal of Antimicrobial Chemotherapy, 2012
- Autoluminescent Mycobacterium tuberculosis for Rapid, Real-Time, Non-Invasive Assessment of Drug and Vaccine EfficacyPLOS ONE, 2012
- Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescenceJournal of Antimicrobial Chemotherapy, 2011
- Noninvasive biophotonic imaging for studies of infectious diseaseFEMS Microbiology Reviews, 2011
- Using Bioluminescence To Monitor Treatment Response in Real Time in Mice with Mycobacterium ulcerans InfectionAntimicrobial Agents and Chemotherapy, 2011
- Imaging tuberculosis with endogenous β-lactamase reporter enzyme fluorescence in live miceProceedings of the National Academy of Sciences, 2010
- Optimisation of Bioluminescent Reporters for Use with MycobacteriaPLOS ONE, 2010
- Fast Standardized Therapeutic-Efficacy Assay for Drug Discovery against TuberculosisAntimicrobial Agents and Chemotherapy, 2010
- Bioluminescent Mycobacterium aurum Expressing Firefly Luciferase for Rapid and High Throughput Screening of Antimycobacterial Drugs in Vitro and in Infected MacrophagesBiochemical and Biophysical Research Communications, 2000
- Rapid methods for counting mycobaacteria—comparison of methods for extraction of mycobacterial adenosine triphosphate (ATP) determined by firefly luciferase assayTubercle, 1985